<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341948</url>
  </required_header>
  <id_info>
    <org_study_id>0150-CSP-000</org_study_id>
    <secondary_id>CDMRP-OR170165</secondary_id>
    <nct_id>NCT04341948</nct_id>
  </id_info>
  <brief_title>Treatment of Post-Operative Pain Following Orthopedic Surgery With SPRINT® Peripheral Nerve Stimulation (PNS) System</brief_title>
  <official_title>Treatment of Post-Operative Pain Following Orthopedic Surgery With SPRINT® Peripheral Nerve Stimulation (PNS) System in a Randomized, Double-Blinded, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SPR Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>SPR Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to gather information about how knee pain changes when small&#xD;
      amounts of electricity are delivered to the nerves in the leg. This study will involve the&#xD;
      use of a Peripheral Nerve Stimulation (PNS) System that is made by SPR Therapeutics (the&#xD;
      sponsor of the study). The SPRINT PNS System was cleared by the FDA for up to 60 days of use&#xD;
      in the back and/or extremities for the management of acute and chronic pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in average pain intensity</measure>
    <time_frame>Baseline and 5-weeks post-Start of Treatment (SOT) thru 8-weeks post-SOT</time_frame>
    <description>Average pain intensity (Question 5 from the Brief Pain Inventory- Short Form, BPI-5).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>During Lead placement at SOT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>24-48 hours post-Lead placement</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>1-week post-SOT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>2-weeks post-SOT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>3-weeks post-SOT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>4-weeks post-SOT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>5-weeks post-SOT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>6-weeks post-SOT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>7-weeks post-SOT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>8-weeks post-SOT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>3-months post-SOT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>6-months post-SOT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>9-months post-SOT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>12-months post-SOT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>During Lead placement at Start of optional Crossover Treatment (SOCT)</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>24-48 hours post-Lead placement SOCT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>2-weeks post-SOCT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>4-weeks post-SOCT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>8-weeks post-SOCT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>3-months post-SOCT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>6-months post-SOCT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>9-months post-SOCT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-Related Adverse Device Effects</measure>
    <time_frame>12-months post-SOCT</time_frame>
    <description>Occurrence and type of study-related AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average pain intensity</measure>
    <time_frame>Baseline, 1-week post-SOT thru 4-weeks post-SOT</time_frame>
    <description>Average pain intensity (Question 5 from the Brief Pain Inventory- Short Form, BPI-5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pain relief</measure>
    <time_frame>Baseline, 1-week post-SOT thru 4-weeks post-SOT, 5-weeks post-SOT thru 8-weeks post-SOT, 3-months post-SOT, 6-months post-SOT, 9-months post-SOT, 12-months post-SOT</time_frame>
    <description>Average pain intensity (Question 5 from the Brief Pain Inventory- Short Form, BPI-5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term durability of average pain intensity</measure>
    <time_frame>Baseline, 3-months post-SOT, 6-months post-SOT, 9-months post-SOT, 12-months post-SOT</time_frame>
    <description>Average pain intensity (Question 5 from the Brief Pain Inventory- Short Form, BPI-5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain medication usage</measure>
    <time_frame>Baseline, 1-week post-SOT thru 4-weeks post-SOT, and 5-weeks post thru SOT-8-weeks post-SOT, 3-months post-SOT, 6-months post-SOT, 9-months post-SOT, 12-months post-SOT</time_frame>
    <description>Medications collected for each diary collection period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Catastrophizing Scale (PCS)</measure>
    <time_frame>Baseline, 4-weeks post-SOT, 8-weeks post-SOT</time_frame>
    <description>PCS is a 13-question instrument to assess rumination (4 questions), magnification (3 questions), and helplessness (6 questions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC)</measure>
    <time_frame>4-weeks post-SOT, 8-weeks post-SOT, 3-months post-SOT, 6-months post-SOT, 9-months post-SOT, 12-months post-SOT</time_frame>
    <description>PGIC assesses the patient's impression of change in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain interference</measure>
    <time_frame>Baseline, 8-weeks post-SOT, 3-months post-SOT, 6-months post-SOT, 9-months post-SOT, 12-months post-SOT</time_frame>
    <description>Measured using the average pain interference (question 9 from the Brief Pain Inventory-SF, BPI-9).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function (i.e. physical recovery)</measure>
    <time_frame>Baseline, 8-weeks post-SOT, 3-months post-SOT, 6-months post-SOT, 9-months post-SOT, 12-months post-SOT</time_frame>
    <description>Measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six Minute Walk Test (6MWT)</measure>
    <time_frame>Baseline, 8-weeks post-SOT, 3-months post-SOT</time_frame>
    <description>The 6MWT measures the distance walked in 6 minutes and will be used to assess walking speed and endurance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Total Knee Replacement</condition>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Group 1 (Treatment)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in Group 1 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Control)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants in Group 2 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Participants will then have the option to crossover and receive stimulation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SPRINT Peripheral Nerve Stimulation (PNS) System</intervention_name>
    <description>The SPRINT System delivers mild electrical stimulation to nerves in the affected limb. The SPRINT System includes two small wires (called &quot;Leads&quot;) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).</description>
    <arm_group_label>Group 1 (Treatment)</arm_group_label>
    <arm_group_label>Group 2 (Control)</arm_group_label>
    <other_name>SPRINT</other_name>
    <other_name>SPRINT System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  At least 21 years old&#xD;
&#xD;
          -  Underwent a primary unilateral total knee replacement procedure&#xD;
&#xD;
          -  Knee pain directly resulting from Total Knee Replacement in affected knee&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Current high opioid use&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 40 kg/m2&#xD;
&#xD;
          -  Conditions with increased risk of infection&#xD;
&#xD;
          -  Implanted electronic device&#xD;
&#xD;
          -  History of bleeding or clotting disorder.&#xD;
&#xD;
          -  Surgery on the affected knee since the primary Total Knee Replacement&#xD;
&#xD;
          -  Uncontrolled Diabetes Mellitus Types I or II&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elizabeth Deyling</last_name>
    <phone>844-378-9108</phone>
    <email>edeyling@sprtherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia DeAguero, MS</last_name>
      <phone>501-214-2410</phone>
      <email>badeaguero@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Johnathan H Goree, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baharin Abdullah</last_name>
      <phone>858-344-4144</phone>
      <email>baabdullah@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Brian M. Ilfeld, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Orthopaedic Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Kostedt, RN</last_name>
      <phone>352-336-6000</phone>
      <email>gkostedt@toi-health.com</email>
    </contact>
    <investigator>
      <last_name>Ajay Antony, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Better Health Clinical Research, Inc</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Helton</last_name>
      <phone>770-252-7562</phone>
      <email>dhelton@gapaincare.com</email>
    </contact>
    <investigator>
      <last_name>Sandeep Vaid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Amusin</last_name>
      <phone>847-570-3558</phone>
      <email>damusin@northshore.org</email>
    </contact>
    <investigator>
      <last_name>David M. Dickerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuroscience Research Center, LLC</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen M. Dionne</last_name>
      <phone>504-894-2864</phone>
      <email>Colleen.dionne@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Yashar Eshraghi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ali K. Valimahomed MD PLLC</name>
      <address>
        <city>Holmdel</city>
        <state>New Jersey</state>
        <zip>07733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandria Nuwar</last_name>
      <phone>732-784-7151</phone>
    </contact>
    <investigator>
      <last_name>Ali Valimahomed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Becton</last_name>
      <phone>919-843-6575</phone>
      <email>michelle_becton@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Stuart Grant, MB, ChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Mungal, BA</last_name>
      <phone>919-613-2609</phone>
      <email>daniel.mungal@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Ohlendorf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain, Postoperative</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Postoperative Complications</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Pain</keyword>
  <keyword>Neurologic Manifestations</keyword>
  <keyword>Signs and Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

